Published in Med Oncol on January 01, 2007
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol (2012) 1.04
Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin J Cancer (2012) 0.95
Molecular imaging of neuroendocrine tumors. Semin Oncol (2010) 0.89
Abdominal mass, anemia, diabetes mellitus, and necrolytic migratory erythema. Dig Dis Sci (2011) 0.79
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med (2013) 0.78
Clinical features of gastroenteropancreatic tumours. Prz Gastroenterol (2015) 0.75
Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? BMC Cancer (2012) 0.75
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology (2017) 0.75
Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case. Surg Today (2014) 0.75
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol (2005) 2.69
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res (2007) 2.16
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology (2012) 2.12
Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res (2008) 1.98
Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med (2014) 1.95
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. Clin Nucl Med (2016) 1.94
Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.45
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer (2011) 1.43
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer (2007) 1.42
⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors. Endocrine (2013) 1.41
Recognizing genes differentially regulated in vitro by the multiple endocrine neoplasia type 1 (MEN1) gene, using RNA interference and oligonucleotide microarrays. Surgery (2006) 1.40
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas (2010) 1.31
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol (2008) 1.30
Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging (2009) 1.30
Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology (2007) 1.26
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med (2012) 1.24
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (2010) 1.23
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface. Glycobiology (2007) 1.21
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab (2005) 1.18
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab (2014) 1.15
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
Chemical characterization of brominated flame retardants and identification of structurally representative compounds. Environ Toxicol Chem (2006) 1.12
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg (2012) 1.07
ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology (2010) 1.07
Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology (2007) 1.06
Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation (2007) 1.05
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg (2008) 1.05
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology (2009) 1.04
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology (2009) 1.03
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust (2010) 1.02
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med (2013) 1.01
Mutational tuning of galectin-3 specificity and biological function. J Biol Chem (2010) 1.01
In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol (2010) 1.01
Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol (2005) 1.00
Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab (2007) 0.98
Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab (2004) 0.97
High 18F-FDG Uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J Nucl Med (2008) 0.97
Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med (2014) 0.97
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept (2004) 0.97
High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg (2008) 0.97
Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res (2002) 0.96
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol (2004) 0.96